These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 20229800)

  • 1. [Recent development of novel reverse transcriptase inhibitors and protease inhibitors against HIV-1 infection].
    Koh Y
    Nihon Rinsho; 2010 Mar; 68(3):512-9. PubMed ID: 20229800
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rationale and experience with reverse transcriptase inhibitors and protease inhibitors.
    Vella S
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 1():S58-61. PubMed ID: 8595511
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current approaches to treatment for HIV-1 infection.
    Powderly WG
    J Neurovirol; 2000 May; 6 Suppl 1():S8-S13. PubMed ID: 10871760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapy of HIV infection.
    Chang YC; Tyring SK
    Dermatol Ther; 2004; 17(6):449-64. PubMed ID: 15571495
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV-1 protease inhibitors.
    Eron JJ
    Clin Infect Dis; 2000 Jun; 30 Suppl 2():S160-70. PubMed ID: 10860901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Development of new reverse transcriptase inhibitors].
    Kodama E
    Nihon Rinsho; 2002 Apr; 60(4):775-9. PubMed ID: 11968787
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Boosted protease inhibitor-based or nonnucleoside reverse transcriptase-based HAART: is there a best choice for antiretroviral-naive HIV-1 infected patients?
    Cuzin L; Allavena C; Morlat P; Dellamonica P
    AIDS Rev; 2008; 10(4):205-11. PubMed ID: 19092976
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiretroviral drug treatment for HIV/AIDS.
    Goldschmidt RH; Moy A
    Am Fam Physician; 1996 Aug; 54(2):574-80, 587-8. PubMed ID: 8701838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A survey of the syntheses of active pharmaceutical ingredients for antiretroviral drug combinations critical to access in emerging nations.
    Pinheiro Edos S; Antunes OA; Fortunak JM
    Antiviral Res; 2008 Sep; 79(3):143-65. PubMed ID: 18571246
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resistance against reverse transcriptase inhibitors.
    O'Brien WA
    Clin Infect Dis; 2000 Jun; 30 Suppl 2():S185-92. PubMed ID: 10860904
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New drugs for old.
    Winston A; Stebbing J
    J HIV Ther; 2005 Mar; 10(1):11-6. PubMed ID: 15951729
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV/AIDS management in office practice. Antiretroviral therapy.
    Hartman AF
    Prim Care; 1997 Sep; 24(3):531-60. PubMed ID: 9271691
    [TBL] [Abstract][Full Text] [Related]  

  • 14. APHS can act synergically with clinically available HIV-1 reverse transcriptase and protease inhibitors and is active against several drug-resistant HIV-1 strains in vitro.
    Pereira CF; Paridaen JT; van de Bovenkamp M; Middel J; Verhoef J; Nottet HS
    J Antimicrob Chemother; 2003 May; 51(5):1181-9. PubMed ID: 12668583
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Practical issues regarding the use of antiretroviral therapy for HIV infection.
    Deeks SG
    West J Med; 1998 Feb; 168(2):133-9. PubMed ID: 9499754
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An introduction to nucleoside and nucleotide analogues.
    Squires KE
    Antivir Ther; 2001; 6 Suppl 3():1-14. PubMed ID: 11678469
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of transmitted nucleoside analogue-resistant HIV-1 strains and pre-existing mutations in pol reverse transcriptase and protease region: outcome after treatment in recently infected individuals.
    Balotta C; Berlusconi A; Pan A; Violin M; Riva C; Colombo MC; Gori A; Papagno L; Corvasce S; Mazzucchelli R; Facchi G; Velleca R; Saporetti G; Galli M; Rusconi S; Moroni M
    Antivir Ther; 2000 Mar; 5(1):7-14. PubMed ID: 10846586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel treatment options for pediatric HIV infection.
    Day E; Buckberry K; Sharland MR; Chakraborty R
    Curr Opin Investig Drugs; 2008 Feb; 9(2):170-5. PubMed ID: 18246519
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High resistance to antiretroviral drugs: the Indian experience.
    Hira SK; Panchal K; Parmar PA; Bhatia VP
    Int J STD AIDS; 2004 Mar; 15(3):173-7. PubMed ID: 15038863
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A decade in HIV treatment: what is the state of the art and how did we arrive.
    Tamari M
    Clin Excell Nurse Pract; 2001; 5(1):4-12. PubMed ID: 11154387
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.